EHC - European Haemophilia Consortium/LinkedIn
Oct 1, 2025, 16:30
Emicizumab Approvals in Europe: European Haemophilia Consortium Shares Key Updates
European Haemophilia Consortium (EHC) posted on LinkedIn:
”Indications of non-factor treatments for haemophilia A are evolving.
In Europe, Emicizumab is approved for routine prophylaxis for moderate haemophilia A with severe bleeding, for severe haemophilia A and for haemophilia A with factor VIII inhibitors.
It is always a good idea to consult local regulatory authorities for the precise current approved use in your area.
Learn more in the EHCucate topic Emicizumab Basics, available on the EHC Academy.”
Stay updated with Hemostasis Today.
-
Jul 9, 2026, 13:16Olivier Mathieu: Innovating the Future of Hemostasis at ISTH 2026
-
Jul 9, 2026, 12:41Thomas Palmer-Dench: Hexokinase Controls Platelet Activation and Hemostasis
-
Jul 9, 2026, 12:19Paschalis Evangelidis: Join Our Special Issue on Thrombosis and Vascular Disorders
-
Jul 9, 2026, 12:16Fernanda Betti Solano: Could Iron Deficiency Be Affecting Your Sleep?
-
Jul 9, 2026, 12:08Andreas Calatzis: What is the Rationale for Collagen-Induced Platelet Aggregation Testing?
-
Jul 9, 2026, 11:54Deepak Pradhan։ Can Withaferin-A Help Combat Drug-Resistant Malaria?
-
Jul 9, 2026, 11:26Peter Zhang: Is Canada Ready for the Gene Therapy Era?
-
Jul 9, 2026, 09:35Pradeebha Muthukumar: Do You Know the Signs of Anemia?
-
Jul 9, 2026, 09:24Maryam Majid: Machine Learning for Anemia Risk Prediction